Abstract: The invention relates to a computer-implemented method of liver resection surgery planning, comprising the steps of: processing (E2) preoperative computed tomographic images (10) of a patient to generate liver, liver lesion (ss) and venous vessels segmentations; pruning the venous vessels segmentation to retain only major vessels and determining (E3) a primary hepatic zone (PHZ) from the retained major vessels; determining (E4) at least one quantitative feature from the primary hepatic zone, the liver segmentation and the liver lesion(s) segmentation; processing (E5) the determined quantitative features with a classification model to determine a liver resection complexity score for the patient.

Abstract: The invention relates to non-biodegradable embolisation microspheres comprising a cross-linked matrix, the matrix being based on at least: a) from 20% to 95% of hydrophilic monomer; b) from 1% to 15% of a non-biodegradable hydrophilic cross-linking monomer; and c) from 1.5% to less than 6% of transfer agent selected from alkyl halides and cycloaliphatic or aliphatic thiols having in particular from 2 to 24 carbon atoms, and optionally having another functional group selected from amino, hydroxy and carboxy groups. The invention further relates to a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle, advantageously for parenteral administration.

Abstract: The present invention relates to a compound of the following formula (A) mainly for use as a radiopaque monomer: The invention further relates to radiopaque embolisation microspheres based at least on: 20% to 90% hydrophilic monomer; 5% to 50% compound of formula (A); 1% to 15% non-biodegradable hydrophilic crosslinking monomer; and ?0.1% to 10% transfer agent. The invention also relates to a pharmaceutical composition comprising at least one embolisation microsphere according to the invention, in association with a pharmaceutically acceptable carrier, advantageously for parenteral administration. The invention further relates to a kit comprising a pharmaceutical composition according to the invention in association with a pharmaceutically acceptable carrier for parenteral administration, and to an injection means.

Abstract: An injection device for injecting into a medical tubing a medical liquid from a medical liquid container, said injection device comprising a body, a piston (6) arranged in the body for travelling along the longitudinal direction, said piston (6), an evacuation path traversing the piston (6), and a float (24) configured for floating on the medical liquid and configured for travelling within a cavity (36) along the longitudinal direction between a blocking configuration in which an obturating part (24a) of the float (24) obturates the passage (38) of the evacuation path, thereby closing the evacuation path, and an open configuration in which the obturating part 24a of the float (24) is spaced apart from the passage (38), thereby letting open the evacuation path, wherein the float (24) has a metacenter (M) which is spaced apart from the top of the obturating part (24a) by a distance less than one third of the height of the float (24).

Abstract: An injection device for injecting a medical liquid, comprising a piston arranged within an inner space delimiting an upper space and a lower space, an evacuation path, said evacuation path traversing the piston the lower space to the upper space of the inner space, a selector between a lower portion and an intermediate portion of the evacuation path, configured for selectively allowing the gas to go through and preventing the medical liquid from going through said selector, a purge valve between the intermediate portion of the evacuation path and an upper portion of the evacuation path and configured for moving between a blocking and a passing configuration which requires an overpressure in the intermediate portion caused by the piston travelling towards the lower end of the body.

Abstract: The present invention relates to method for medical imaging, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (a) Obtaining at least one candidate pre-contrast image and a candidate contrast image respectively depicting a body part prior to and after an injection of a first dose of contrast agent, wherein said first dose is higher than a predetermined low dose, the predetermined reduced dose being lower than a predetermined standard dose; a convolutional neural network, CNN, being trained to reconstruct, from at least a pre-contrast input image and a low dose contrast input image respectively depicting a body part prior to and after an injection of said low dose of contrast agent, a standard dose contrast image depicting said body part after an injection of said standard dose of contrast agent; (b) Simulating an injection of a second dose of contrast agent which is higher than the standard dose, wherein said simulating comp

Abstract: An injection device (1) for delivering a medical fluid, comprising an interface module (4) configured to receive a syringe (6), the interface module (4) defining a reception space (40) adapted to receive a flange (12a) in the outer periphery of a barrel (10) of the syringe (6), a drive member (8) configured to couple a piston of the syringe, and to translate along a longitudinal axis (X). The interface module (4) comprises a lateral opening (46) defined between two supporting members (50) of the interface module (4) and extending radially in a first radial direction from the longitudinal axis (X), said lateral opening (46) adapted for a radial translation of the syringe (6) in the first radial direction to a loaded position in which the flange (12a) of the syringe (6) is received in the reception space and the barrel (10) of the syringe (6) extends along the longitudinal axis (X).

Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.

Abstract: The present invention relates to a method for processing at least a pre-contrast image depicting a body part prior to an injection of contrast agent, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (a) Obtaining said pre-contrast image; (b) Determining, by application of a prediction model to said pre-contrast image candidate value(s) of at least one injection parameter of said injection of contrast agent, such that the sequence of said pre-contrast image and at least a contrast image depicting said body part during injection of contrast agent in accordance with the determined candidate value(s) of said injection parameter(s) minimizes a radiation dose.

Abstract: The present invention relates to a method for generating at least one contrast tomogram depicting a target body part during an injection of contrast agent, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (a) Obtaining a pre-contrast tomogram of said target body part prior to the injection of contrast agent, and raw projection data acquired over a limited rotation angle span during the injection of contrast agent; (b) Segmenting said target body part on the pre-contrast tomogram; (c) Generating the contrast tomogram, by application of a tomosynthesis reconstruction model to said segmented pre-contrast tomogram and the obtained raw projection data.

Abstract: The present invention relates to a process for preparing the 2-bromoglutaric acid diester of formula (I) below: comprising the formation of the 2-hydroxyglutaric acid diester of formula (II) by reaction of butyrolactone acid of formula (BA) with the alcohol of formula ROH, in the presence of an acid such as sulfuric acid; and bromination of the 2-hydroxyglutaric acid diester of formula (II), by sparging with gaseous hydrobromic acid. The present invention also relates to a 2-bromoglutaric acid diester of formula (I), having a degree of purity determined by HPLC analysis of greater than or equal to 90%.

Abstract: The present invention relates to a method for processing an inputted perfusion sequence, by means of a convolutional neural network, CNN, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (b) extracting, using an encoder branch of the CNN, a plurality of initial n+1-dimensional features maps representative of the inputted perfusion sequence at different scales, n?3, said CNN further comprising a decoder branch and skip connections between the encoder branch and the decoder branch, each skip connection projecting the initial n+1-dimensional features maps into initial n-dimensional feature maps; (c) generating, using said decoder branch of the CNN, a plurality of enriched n-dimensional feature maps also representative of representative of the inputted perfusion sequence at different scales, each enriched n-dimensional feature map incorporating the information from the initial n-dimensional feature maps of smaller or equal scal

Abstract: The present invention relates to a method for processing at least a pre-contrast image depicting a body part prior to an injection of contrast agent, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (a) Obtaining said pre-contrast image; (b) Determining candidate value(s) of at least one injection parameter of said injection of contrast agent by application of a prediction model to said pre-contrast image, such that a theoretical contrast image depicting said body part during injection of contrast agent in accordance with the determined candidate value(s) of said injection parameter(s) is expected to present a target quality level.

Abstract: The present invention relates to an embolizing emulsion comprising iodinated oil and an aqueous phase comprising a water-soluble contrast agent for use in the treatment of inflammatory hypervascularization associated with a musculoskeletal disorder.

Abstract: An injection device (1) for injecting a medical liquid, comprising: —a piston (6) arranged within an inner space (4) delimiting an upper space (4b) and a lower space (4a), —an evacuation path, said evacuation path traversing the piston (6) the lower space (4a) to the upper space (4b) of the inner space, —a selector (24) between a lower portion (17a) and an intermediate portion (17b) of the evacuation path, configured for selectively allowing the gas to go through and preventing the medical liquid from going through said selector (24, 50, 60), —a purge valve (22) between between a blocking and a passing configuration which requires an overpressure in the intermediate portion (17b) caused by the piston (6) travelling towards the lower end of the body (2).

Abstract: The present invention relates to a process for preparing the macrocyclic ligand of formula (L) below: involving: i) decomplexation of the complex of formula (II): constituted of at least 80% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: ii) removing the gadolinium salt formed in step i), for example by filtration, and ii) recovering the free macrocyclic ligand of formula (L). The present invention also relates to a composition comprising the diastereoisomerically enriched complex of formula (II) and the macrocyclic ligand of formula (L).

Abstract: A medical container assembly is disclosed having an adapter assembly that fluidly connects with a medical container having a volume of medical fluid to accommodate multiple injections. The adapter assembly includes a spike assembly (300) that fluidly connects with the medical container, along with a spike interface cover (200) that detachably connects with the spike assembly (300). Features are incorporated by the spike assembly (300) to reduce the potential that the spike assembly (300) will be used with multiple medical containers. The spike interface cover (200) is detachably connected with the spike assembly (300) and includes features that allows the spike interface cover (200) to be used with a spike assembly (300) installed on one container, and to thereafter allow this same spike interface cover (200) to be used with another spike assembly (300) installed on another container.

Abstract: The present invention relates to a process for preparing the 2-bromoglutaric acid diester of formula (I) below: comprising the formation of the 2-hydroxyglutaric acid diester of formula (II) by reaction of butyrolactone acid of formula (BA) with the alcohol of formula ROH, in the presence of an acid such as sulfuric acid; and bromination of the 2-hydroxyglutaric acid diester of formula (II), by sparging with gaseous hydrobromic acid. The present invention also relates to a 2-bromoglutaric acid diester of formula (I), having a degree of purity determined by HPLC analysis of greater than or equal to 90%.

Abstract: A mechanism is provided for seed relabeling for seed-based slice-wise lesion segmentation. The mechanism receives a lesion mask for a three-dimensional medical image volume. The lesion mask corresponds to detected lesions in the medical image volume and wherein each detected lesion has a lesion contour. The mechanism generates a distance map for a given two-dimensional slice in the medical image volume based on the lesion mask. The distance map comprises a distance to a lesion contour for each voxel of the given two-dimensional slice. The mechanism performs local maxima identification to select a set of local maxima from the distance map such that each local maximum has a value greater than its immediate neighbor points. The mechanism performs seed relabeling based on the distance map and the set of local maxima to generate a set of seeds. Each seed represents a center of a distinct component of a lesion contour.

Abstract: Mechanisms are provided to implement an automated medical image processing pipeline selection (MIPPS) system. The MIPPS system receives medical image data associated with a patient electronic medical record and analyzes the medical image data to extract evidence data comprising characteristics of one or more medical images in the medical image data indicative of a medical image processing pipeline to select for processing the one or more medical images. The evidence data is provided to a machine learning model of the MIPPS system which selects a medical image processing pipeline based on a machine learning based analysis of the evidence data. The selected medical image processing pipeline processes the medical image data to generate a results output.